Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Brokerages

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $7.40.

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATNM. Wellington Management Group LLP acquired a new stake in Actinium Pharmaceuticals in the third quarter worth about $112,000. Geode Capital Management LLC boosted its holdings in shares of Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after acquiring an additional 19,843 shares during the last quarter. Barclays PLC increased its stake in shares of Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of Actinium Pharmaceuticals during the fourth quarter worth $32,000. Finally, Los Angeles Capital Management LLC lifted its position in Actinium Pharmaceuticals by 25.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after purchasing an additional 42,770 shares during the period. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Price Performance

ATNM stock opened at $1.26 on Friday. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24. The business has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.42. The company has a market capitalization of $39.31 million, a P/E ratio of -0.91 and a beta of -0.27.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).